Skip Navigation
Search Menu
Find an Expert

 


Peng Huang, Ph.D.

Photo of Dr. Peng Huang, Ph.D.

Associate Professor of Oncology

Background

Titles

  • Associate Professor of Oncology

Research & Publications

Research Summary

Dr. Huang’s research mainly focuses on global assessment of treatment effect when multiple endpoints are evaluated simultaneously. This includes optimal study design with multiple endpoints, sequential clinical trial data monitory, and final data analysis of multiple endpoints. Dr. Huang has received NIH research grant award in the development of global statistical test. She won the 1997 Shewell Award from American Society for Quality Control for her innovative minimum aberration split-plot design which has been adopted into the widely used SAS software.

At Johns Hopkins University, Dr. Huang’s main role is to provide biostatistics support in study design and data analysis. She is a full member of Clinical Research Review Committee at The Sidney Kimmel Comprehensive Cancer Center, the leading biostatistician in breast cancer, liver cancer, and imaging studies. Dr. Huang has extensive experiences in statistical design and data analysis for clinical trials and lab experiments. Outside Johns Hopkins, Dr. Huang serves in multiple NIH/CSR and NIH/NCI study section review panels since 2002. Currently, Dr. Huang is a member of NIH/CSR Clinical Neuroscience and Disease (CNN) Study Section (a six-year appointment).

 

Selected Publications

  1. Higgins M, Jelovac D, Barnathan E, Blair B, SlaterS, Powers P, Zorzi J, Jeter S, Oliver G, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy K, Bachman K, Greshock J, Wolff A, and Park B. Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood. Clinical Cancer Research. 2012; 18:3462-3469.
  2. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Kim J, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European Journal of Cancer. 2012; 48:202-208.
  3. Fackler MJ, Umbricht C, Williams D, Argani P, Cruz L, Merino V, Teo W, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray J, Wolff A, Cope L, Sukumar S. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Research. 2011; 1;71(19):6195-207.
  4. Schaefer NG, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists. J Nucl Med. 2011;52:830-838. "not supported through NIH funding"
  5. Keizman D, Huang P, Eisenberger MA, Pili R, Kim J, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. European Journal of Cancer. 2011 September; 47(13): 1955-1961. PMC393247.
  6. Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Walczak J, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation. Prostate. 2011 Mar 22. 71:1608-1615. PMC393222.
  7. Cerutti J. Oler G, Delcelo R, Gerardt R, Michaluart P, Souza S, Galante P, Huang P, Riggins G. PVALB, a new Hürthle adenoma marker identified through gene expression profiling improves diagnostic accuracy of a thyroid nodule. J Clin Endocrinol Metab. 2011. 96(1). Doi:10.1210/jc.2010-1318 http://jcem.endojournals.org/cgi/rapidpdf/jc.2010-1318v1
  8. Yu F, Chen MH, Kuo L, Huang P, Yang W. Bayesian Hierarchical Modeling for Detecting DE Genes from the EST Data. Biometrics. 2011. 67, 142-150.
  9. Khouli R, Jacobs M, Mezban S, Huang P, Kamel I, Macura K, Bluemke D. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging, Radiology 2010. 256: 64-73. PMCID: PMC2897691
  10. Demokan S, Chang X, Chuang A, Mydlarz WK, Kaur J, Huang P, Khan Z, Khan T, Ostrow KL, Brait M, Hoque MO, Liegeois NJ, Sidransky D, Koch W, Califano JA. KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. International Journal of Cancer. 2010. Vol 127(10): 2351-2359 "not supported through NIH funding"
Is this you? Edit Profile